|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
When all GLP-1RAs were compared with each other, no clinically meaningful differences were observed in weight loss, blood pressure reduction or hypoglycaemia risk.
|
27981757 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The GLP-1RA may be a choice of therapy when weight control and avoidance of hypoglycemia are important, and patients with high risk of cardiovascular disease might also favor choosing GLP-1RA.
|
29272081 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observed benefits in GV and hypoglycemia may contribute to the cardiovascular outcome reduction seen with GLP-1 RA therapy and should be investigated further.
|
27913575 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia.
|
27975209 |
2017 |
|
Hypoglycemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BI in combination with GLP-1 RAs appears to be an effective intensification strategy, further reducing A1C levels and hypoglycemia frequency compared to increasing BI doses.
|
28816532 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Besides improving glycemic control, the GLP-1RAs have other beneficial effects such as weight loss and a low risk of hypoglycemia.
|
28102093 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of hypoglycemia with GLP-1RAs is minimal; however, GLP-1RAs are associated with gastrointestinal adverse events and raise concerns regarding pancreatitis.
|
28526416 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Expert opinion: IDegLira provides superior glycaemic control and mitigates the primary adverse effects associated with insulin therapy (weight gain and hypoglycaemia) and GLP-1RAs (gastrointestinal side effects) with no indication of additive effects.
|
28150516 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass.
|
28855269 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In a study comparing the addition of exenatide QW and pioglitazone with the addition of basal-bolus insulin in 101 people receiving sulfonylureas and metformin with baseline HbA1c >10%, HbA1c fell from >11% by >4% compared with <4%, respectively, and the GLP-1RA plus thiazolidinedione treatment was associated with less weight gain and hypoglycemia.What can we conclude?
|
28589542 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
As its glucose-lowering action is glucose dependent, a GLP-1 receptor agonist (GLP-1RA) achieves these benefits with a lower risk of hypoglycemia compared with other diabetes therapies.
|
28721686 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of the GLP-1RA liraglutide on counterregulatory responses and GE rate during hypoglycaemia in persons with T1D.
|
27868372 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, I provide a clinical update of glucagon-like peptide-1 receptor agonists (GLP-1RAs), a class of incretin-based, injectable antidiabetes therapies which improve fasting and postprandial blood glucose control through glucose-dependent pancreatic islet cell hormone secretion without significant risks for hypoglycemia.
|
28942790 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Addition of GLP-1 RA to basal insulin provided improved glycemic control, led to weight reduction and similar hypoglycemia rates versus an intensified insulin strategy; however, symptomatic hypoglycemia rates were significantly lower when compared with a basal insulin plus RAI.
|
28294702 |
2017 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1As decreased risks of all-cause and CV mortality and severe hypoglycemia, whereas DPP-4Is had no effect on CV outcomes but increased risks in acute pancreatitis and hypoglycemia.
|
28249585 |
2017 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The dual use of basal insulin plus GLP-1 RA is non-inferior compared with basal insulin plus a single injection of prandial insulin at the largest meal and compared with twice daily-dosed premixed insulins; and this combination is associated with weight loss and less hypoglycemia.
|
29796245 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium glucose cotransporter 2 inhibitors (SGLT2i) are of particular interest in type 2 diabetes treatment strategies, due to their efficacy in reducing HbA1c with a low risk of hypoglycaemia, to their positive effects on body weight and blood pressure and in light of their effects on cardiovascular risk and on nephroprotection emerged from the most recent cardiovascular outcome trials.
|
29334278 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Glucagon like peptide 1 receptor agonists (GLP-1 RAs) are also effective in terms of glycemic control and associated with weight loss and low risk of hypoglycemia.
|
29636825 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Through a wealth of studies, including both placebo-controlled and active-controlled studies, GLP-1 RAs have demonstrated high glycemic efficacy and ability to facilitate weight loss, with minimal risk of hypoglycemia, potential to restore beta cell function, and evidence for improved cardiovascular outcomes in those at risk.
|
29364586 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The risk of hypoglycemia was increased with TZD or GLP-1RA.
|
29511288 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results for third-line agents added to metformin and TZDs were comparable, showing similar HbA1c reduction and risk of hypoglycaemia between SGLT-2 inhibitors and GLP-1RAs, and a slightly greater reduction in body weight with SGLT-2 inhibitors vs GLP-1RAs.
|
29205774 |
2018 |
|
Hypoglycemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
GLP-1 RA intensifiers had equivalent glycemic control to RAI or other injectables, with a nonsignificantly lower risk of hypoglycemia and reduction in body weight.
|
29975575 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 therapy has the potential to lower glucose without causing hypoglycaemia.
|
29866735 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, the combination of SU plus glucagon-like peptide-1 receptor agonist (GLP-1RA) was associated with the most significant increase in the risk of hypoglycemia.
|
30148851 |
2018 |
|
Hypoglycemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 agonists yield greater reduction in HbA1c and weight as compared to DPP-4 inhibitors, with increased incidence of gastrointestinal symptoms but not hypoglycaemia.
|
29364587 |
2018 |